Pancreatic cancer is a lethal disease and its prognosis remains dismal. The modest results of existing available treatments inthe second line setting reveal the need of new therapeutic strategies. In this year’s American Society of Clinical Oncology(ASCO) Annual Meeting two remarkable trials and one retrospective analysis were presented regarding this vulnerablegroup of patients. According to the published results, docetaxel plus oxaliplatin (Abstract #4034), selumetinib plus erlotinib(Abstract #4014) and nab-paclitaxel (Abstract #e15057) have shown promising efficacy and manageable toxicity that shouldbe elucidated and confirmed by new prospective, large, randomized trials.
Muhammad Wasif Saif, Kostas N Syrigos, Vasilis Stefanos Ramfidis